Clearside Biomedical (STU:CLM0) Cyclically Adjusted Revenue per Share: €2.03 (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CLM0 Clearside Biomedical Inc STU:CLM0
49 GF Score
Price €4.35
GF Value €110.06
! 7 Warning Signs
View Full Analysis

What is Clearside Biomedical Cyclically Adjusted Revenue per Share?

Clearside Biomedical STU:CLM0 49 Cyclically Adjusted Revenue per Share is €2.03 as of Sep. 2025. GuruFocus rates STU:CLM0 with a GF Score™ of 49/100 and a GF Value™ of €110.06. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Clearside Biomedical's adjusted revenue per share for the three months ended in Sep. 2025 was €0.033. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €2.03 for the trailing ten years ended in Sep. 2025.

During the past 12 months, Clearside Biomedical's average Cyclically Adjusted Revenue Growth Rate was -4.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-26), Clearside Biomedical's current stock price is €4.35. Clearside Biomedical's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2025 was €2.03. Clearside Biomedical's Cyclically Adjusted PS Ratio of today is 2.14.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Clearside Biomedical was 11.21. The lowest was 0.01. And the median was 4.98.


Clearside Biomedical  (STU:CLM0) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Clearside Biomedical's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4.35/2.03
=2.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Clearside Biomedical was 11.21. The lowest was 0.01. And the median was 4.98.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Clearside Biomedical Cyclically Adjusted Revenue per Share Related Terms


Clearside Biomedical Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Clearside Biomedical's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clearside Biomedical Cyclically Adjusted Revenue per Share Chart

Clearside Biomedical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 1.76

Clearside Biomedical Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.65 1.76 1.72 1.53 2.03

STU:CLM0 vs LYRA, EVFM, ATXI: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Clearside Biomedical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clearside Biomedical Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearside Biomedical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Clearside Biomedical's Cyclically Adjusted PS Ratio falls into.


STU:CLM0
49GF Score
Clearside Biomedical Inc STU:CLM0
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clearside Biomedical Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Clearside Biomedical's adjusted Revenue per Share data for the three months ended in Sep. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2025 (Change)*Current CPI (Sep. 2025)
=0.033/324.8000*324.8000
=0.033

Current CPI (Sep. 2025) = 324.8000.

Clearside Biomedical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201512 0.000 236.525 0.000
201603 0.418 238.132 0.570
201606 0.007 241.018 0.009
201609 0.003 241.428 0.004
201612 0.003 241.432 0.004
201703 0.003 243.801 0.004
201706 0.069 244.955 0.091
201709 0.077 246.819 0.101
201712 0.027 246.524 0.036
201803 0.000 249.554 0.000
201806 0.000 251.989 0.000
201809 0.000 252.439 0.000
201812 0.012 251.233 0.016
201903 0.018 254.202 0.023
201906 0.016 256.143 0.020
201909 0.050 256.759 0.063
201912 0.618 256.974 0.781
202003 1.243 258.115 1.564
202006 0.104 257.797 0.131
202009 0.930 260.280 1.161
202012 0.003 260.474 0.004
202103 0.008 264.877 0.010
202106 0.168 271.696 0.201
202109 0.659 274.310 0.780
202112 5.219 278.802 6.080
202203 0.079 287.504 0.089
202206 0.091 296.311 0.100
202209 0.067 296.808 0.073
202212 0.077 296.797 0.084
202303 0.001 301.836 0.001
202306 0.229 305.109 0.244
202309 0.195 307.789 0.206
202312 1.398 306.746 1.480
202403 0.046 312.332 0.048
202406 0.017 314.175 0.018
202409 0.188 315.301 0.194
202412 0.058 315.605 0.060
202503 0.420 319.799 0.427
202506 0.082 322.561 0.083
202509 0.033 324.800 0.033

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €2.03 mean?
Clearside Biomedical (STU:CLM0) has a Cyclically Adjusted Revenue per Share of €2.03 as of Sep. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Clearside Biomedical and its competitors.
Is Clearside Biomedical's Cyclically Adjusted Revenue per Share too high?
Clearside Biomedical's current Cyclically Adjusted Revenue per Share is €2.03. Overall, Clearside Biomedical has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Clearside Biomedical's Cyclically Adjusted Revenue per Share compare to LYRA and EVFM?
Clearside Biomedical's Cyclically Adjusted Revenue per Share of €2.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Clearside Biomedical and its competitors. Clearside Biomedical's current Cyclically Adjusted Revenue per Share is €2.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearside Biomedical stock overvalued right now?
Clearside Biomedical (STU:CLM0) has a current Cyclically Adjusted Revenue per Share of €2.03. The stock's GF Value™ is €110.06, compared to a current price of €4.35 — trading 96% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €2.03. Clearside Biomedical's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Clearside Biomedical (STU:CLM0), the current Cyclically Adjusted Revenue per Share is €2.03 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clearside Biomedical (STU:CLM0) Overvalued in 2026?

Based on GuruFocus' analysis, Clearside Biomedical stock appears to be undervalued. The current stock price of €4.35 is trading 96% below its estimated GF Value™ of €110.06.

Key valuation signals for STU:CLM0:

  • Cyclically Adjusted Revenue per Share: €2.03
  • GF Value™: €110.06 vs. price of €4.35 (96% below fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the STU:CLM0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Clearside Biomedical Business Description

Other Exchanges CLSDQ:USA
Address 900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
49GF Score

Get the complete analysis for STU:CLM0

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.35
Price
€110.06
GF Value